Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Summary of Significant Accounting Policies

Schedule of research and development costs

	Year Ended		Year Ended		Year Ended
	December 31, 2025		December 31, 2024		December 31, 2023
	(In thousands)
Barzolvolimab/Anti-KIT Program	$	198,329	$	123,750	$	79,913
CDX-622		18,958		17,341		16,299
Other Programs (a)		27,787		22,459		21,799
Total R&D Expense	$	245,074	$	163,550	$	118,011

(a) Other program expenses primarily include research and development expenses related to early-stage programs, revenue-generating programs and discontinued programs.

	Year Ended		Year Ended		Year Ended
	December 31, 2025		December 31, 2024		December 31, 2023
	(In thousands)
Personnel	$	57,204	$	51,906	$	40,121
Laboratory Supplies		5,997		5,611		5,358
Facility		5,301		5,094		4,970
Product Development (b)		161,096		90,604		59,319
Other Expenses (c)		15,476		10,335		8,243
Total R&D Expense	$	245,074	$	163,550	$	118,011

(b) Product development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product manufacturing.

(c) Other expenses primarily include research and development consulting, insurance, licensing and software expenses.

Schedule of potentially dilutive common shares that have not been included in the net loss per common share calculations because the effect would have been anti-dilutive

	Year Ended December 31,
	2025	2024	2023
Stock options	9,134,278	7,540,109	6,378,924